Aki Prihti is a Non-Executive Director of Aranda Pharma Ltd. Aki has over 15 years of experience with life science growth companies, both in operational and board roles and as an investor. Aki is one of the founders of Inveni Capital, a life sciences focused venture capital fund. Aki has been involved in setting up, developing, as well as fundraising for, several life science companies and serves currently as a board member in Aranda Pharma Oy, Herantis Pharma Oyj and Priaxon AG. Previously Aki has served in the boards of among others Medeia Therapeutics Oy, Medtentia International Oy and Onbone Oy and has worked for an international investment bank in London. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland. Currently Aki serves as CEO of Aplagon Oy, a Finnish drug development company focused on vascular intervention related thrombosis. Aki Prihti is a Non-Executive Director of Aranda Pharma Ltd. Aki has over 15 years of experience with life science growth companies, both in operational and board roles and as an investor. Aki is one of the founders of Inveni Capital, a life sciences focused venture capital fund. Aki has been involved in setting up, developing, as well as fundraising for, several life science companies and serves currently as a board member in Aranda Pharma Oy, Herantis Pharma Oyj and Priaxon AG. Previously Aki has served in the boards of among others Medeia Therapeutics Oy, Medtentia International Oy and Onbone Oy and has worked for an international investment bank in London. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland. Currently Aki serves as CEO of Aplagon Oy, a Finnish drug development company focused on vascular intervention related thrombosis.

Pharmaceutical industry